A 58365 A

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 571139

CAS#: 87896-52-4 (A)

Description: A 58365 A is an angiotensin converting enzyme (ACE) inhibitor isolated from Streptomyces chromofuscus. It is used to treat hypertension and congestive heart failure.


Chemical Structure

img
A 58365 A
CAS# 87896-52-4 (A)

Theoretical Analysis

MedKoo Cat#: 571139
Name: A 58365 A
CAS#: 87896-52-4 (A)
Chemical Formula: C12H13NO6
Exact Mass: 267.0743
Molecular Weight: 267.24
Elemental Analysis: C, 53.93; H, 4.90; N, 5.24; O, 35.92

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 87896-52-4 (A)   87896-53-5 (B)  

Synonym: A 58365A; A-58365A; A58365A

IUPAC/Chemical Name: 6-Indolizinepropanoic acid, 3-carboxy-1,2,3,5-tetrahydro-8-hydroxy-5-oxo-, (-)-

InChi Key: HMWIHWAAIYAMFZ-UHFFFAOYSA-N

InChi Code: InChI=1S/C12H13NO6/c14-9-5-6(1-4-10(15)16)11(17)13-7(9)2-3-8(13)12(18)19/h5,8,14H,1-4H2,(H,15,16)(H,18,19)

SMILES Code: O=C(O)CCC1=CC(O)=C2CCC(C(O)=O)N2C1=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 267.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Vinazzer H, Farine JC. Double-blind cross-over study of the effect of sultosilic acid piperazine salt (A-585) and bezafibrate in primary hyperlipoproteinemia. Atherosclerosis. 1983 Nov;49(2):109-18. PubMed PMID: 6686778.

2: Vinazzer H. [Comparison of the antilipemic effect of bezafibrate with that of piperazine-sultosilate (A 585). A crossed double-blind study]. Wien Klin Wochenschr. 1984 Dec 21;96(24):889-93. German. PubMed PMID: 6152088.

3: Rodríguez L, Demestre I, Sagarra R, Laporte J, Esteve A. [Toxicologic study of piperazine sultosylate (A-585)]. Arch Farmacol Toxicol. 1979 Dec;5(3):281-3.Spanish. PubMed PMID: 546355.

4: Casellas Bernat A, Ribas Grau M, Casellas Bernat G, Riera de Barcia L, Alou Llado M, Solivellas Antich S. [Clinical effectiveness of piperazine sultosylate in the hyperlipidemias]. Rev Clin Esp. 1981 Apr 25;161(1):5-8. Spanish. PubMed PMID: 7255818.

5: Rodríguez L, Roser R, Palacios G, Sagarra R, Esteve A. [Hypolipemic activity of piperazine sultosylate (A-585) in the rat and chicken]. Arch Farmacol Toxicol. 1979 Dec;5(3):272-4. Spanish. PubMed PMID: 546353.

6: Rodríguez L, Parés S, Laporte J, Roser R, Esteve J. [Effect of piperazine sultosylate (A-585) on hypertriglyceridemia induced by ethanol in man]. Arch Farmacol Toxicol. 1979 Dec;5(3):235-7. Spanish. PubMed PMID: 546346.

7: Masana L, Villoria J, Sust M, Ros E, Plana N, Pérez-Jiménez F, Franco M, Oliván JJ, Pintó X, Videla S. Treatment of type IIb familial combined hyperlipidemia with the combination pravastatin-piperazine sultosilate. Eur J Pharmacol. 2004 Aug 2;496(1-3):205-12. PubMed PMID: 15288592.